PMID- 28723233
OWN - NLM
STAT- MEDLINE
DCOM- 20180129
LR  - 20211204
IS  - 1651-226X (Electronic)
IS  - 0284-186X (Linking)
VI  - 56
IP  - 12
DP  - 2017 Dec
TI  - Treatment patterns and clinical outcomes with pazopanib in patients with advanced 
      soft tissue sarcomas in a compassionate use setting: results of the SPIRE 
      study().
PG  - 1769-1775
LID - 10.1080/0284186X.2017.1332779 [doi]
AB  - BACKGROUND: A named patient program (NPP) was designed to provide patients with 
      advanced soft-tissue sarcoma (aSTS) access to pazopanib, a multitargeted tyrosine 
      kinase inhibitor. The SPIRE study was a retrospective chart review of 
      participating patients. PATIENTS AND METHODS: Eligibility criteria for the NPP 
      and SPIRE mirrored those of the pivotal phase-III study, PALETTE, which compared 
      pazopanib with placebo in patients >/=18 years with aSTS and whose disease had 
      progressed during or following prior chemotherapy or were otherwise unsuitable 
      for chemotherapy. Outcomes of interest included treatment patterns, treatment 
      duration, relative dose intensity, progression-free survival (PFS), overall 
      survival (OS), clinical benefit rate, adverse events (AEs) and reasons for 
      treatment discontinuation. RESULTS: A total of 211 patients were enrolled (median 
      age 56 years; 60% female). Most patients received pazopanib in second- and 
      third-line therapy (28.0% and 28.4%, respectively), followed by fourth line 
      (19.0%) and >/= fifth line (18.5%). The median duration of pazopanib treatment was 
      3.1 months (95% CI: 2.8-3.8), with a mean daily dose of 715 mg equating to 92% of 
      recommended dose. Median OS was 11.1 months and clinical benefit rate was 46%. 
      There was evidence of some clinical benefit across most histological subtypes. At 
      study end, 40% of patients were alive and of these, 18% remained on pazopanib. 
      Thirteen percent (13%) of patients discontinued pazopanib due to AEs. 
      CONCLUSIONS: The SPIRE study demonstrated activity of pazopanib in heavily 
      pretreated aSTS patients in a compassionate use setting. No new safety concerns 
      were noted. Reassuringly, the relative dose intensity of pazopanib was 92%.
FAU - Gelderblom, Hans
AU  - Gelderblom H
AD  - a Department of Medical Oncology , Leiden University Medical Centre , Leiden , 
      the Netherlands.
FAU - Judson, Ian R
AU  - Judson IR
AD  - b Sarcoma Unit , The Royal Marsden NHS Foundation Trust , London , UK.
FAU - Benson, Charlotte
AU  - Benson C
AD  - b Sarcoma Unit , The Royal Marsden NHS Foundation Trust , London , UK.
FAU - Merimsky, Ofer
AU  - Merimsky O
AD  - c Unit of Bone and Soft Tissue Oncology , Tel-Aviv Sourasky Medical Center and 
      Tel-Aviv University Sackler School of Medicine , Tel-Aviv , Israel.
FAU - Grignani, Giovanni
AU  - Grignani G
AD  - d Divisione Oncologia Medica , Candiolo Cancer Institute - FPO I.R.C.C.S. , 
      Candiolo , Italy.
FAU - Katz, Daniela
AU  - Katz D
AD  - e Hadassah-Hebrew University Medical Center , Jerusalem , Israel.
FAU - Freivogel, Klaus W
AU  - Freivogel KW
AD  - f United BioSource (Germany) GmbH , Loerrach , Germany.
FAU - Stein, Dara
AU  - Stein D
AD  - g United BioSource Corporation , Quebec , Canada.
FAU - Jobanputra, Minesh
AU  - Jobanputra M
AD  - h bluebird bio , London , UK.
FAU - Mungul, Arron
AU  - Mungul A
AD  - i Bristol-Myers Squibb , Uxbridge , UK.
FAU - Manson, Stephanie C
AU  - Manson SC
AD  - j Novartis Oncology , East Hanover , NJ , USA.
FAU - Sanfilippo, Roberta
AU  - Sanfilippo R
AD  - k Adult Mesenchymal Tumor Medical Oncology Unit , Fondazione IRCCS Istituto 
      Nazionale Tumori , Milan , Italy.
LA  - eng
PT  - Journal Article
DEP - 20170719
PL  - Sweden
TA  - Acta Oncol
JT  - Acta oncologica (Stockholm, Sweden)
JID - 8709065
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Indazoles)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
RN  - 7RN5DR86CK (pazopanib)
SB  - IM
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Compassionate Use Trials
MH  - Disease-Free Survival
MH  - Female
MH  - Hemangiosarcoma/drug therapy/pathology
MH  - Humans
MH  - Indazoles
MH  - Leiomyosarcoma/drug therapy/pathology
MH  - Lung Neoplasms/drug therapy/secondary
MH  - Male
MH  - Middle Aged
MH  - Pyrimidines/*therapeutic use
MH  - Retrospective Studies
MH  - Sarcoma/*drug therapy/pathology
MH  - Sarcoma, Synovial/drug therapy/pathology
MH  - Solitary Fibrous Tumors/drug therapy/pathology
MH  - Sulfonamides/*therapeutic use
MH  - Survival Rate
MH  - Time Factors
MH  - Uterine Neoplasms/drug therapy/pathology
EDAT- 2017/07/21 06:00
MHDA- 2018/01/30 06:00
CRDT- 2017/07/21 06:00
PHST- 2017/07/21 06:00 [pubmed]
PHST- 2018/01/30 06:00 [medline]
PHST- 2017/07/21 06:00 [entrez]
AID - 10.1080/0284186X.2017.1332779 [doi]
PST - ppublish
SO  - Acta Oncol. 2017 Dec;56(12):1769-1775. doi: 10.1080/0284186X.2017.1332779. Epub 
      2017 Jul 19.